Mark Barrett, is co-founder and CEO of Lassen. Mark is an executive leader with more than twenty years of experience in the research, development, partnering, and commercialization of innovative treatments and has held senior management positions in global biotech and pharma companies. Mark is an Entrepreneur-in-residence with Frazier Healthcare Partners where he founded Lassen. Previously, he served as Global Head of Strategy & Business Development at Sanofi Genzyme and was a member of the company’s executive leadership team responsible for managing Sanofi Genzyme’s €5 billion global business including franchises in rare diseases, immunology, multiple sclerosis, and oncology. Mark was a member of Johnson & Johnson’s global business development group responsible for a range of strategic partnering and acqusition activities. Mark has been responsible for licensing and M&A deals with an aggregate value of over $3 billion, including $125+ million in venture financings, and the creation of eight biotech startups. His business development activities have resulted in successful collaborative worldwide commercialization of blockbuster products, global co-development programs including 250,000+ patients, enabling R&D from innovative early stage research to late stage product development and commercialization. Mark holds an M.B.A. from the University of California, Berkeley and a B.S. in Biology from Duke University
